TB-500 vs GHK (Glycyl-Histidyl-Lysine)

TB-500 and GHK (Glycyl-Histidyl-Lysine) represent two fundamentally different classes of research peptides. TB-500 is a synthetic fragment of thymosin beta-4, designed to mimic its cell-migration and repair functions, with a modest human trial base. GHK is a naturally occurring tripeptide with broad gene-regulatory effects, studied extensively in cell culture and preclinical models. Their overlap in wound healing research belies stark differences in mechanism and evidence strength. This comparison clarifies these distinctions to guide informed experimental choices.

TB-500 is a synthetic 7-amino-acid peptide (Ac-LKKTETQ, MW ~889 g/mol) derived from the active region of thymosin beta-4. It promotes actin polymerization and cell migration, key processes in tissue repair. Research includes a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults that reported minimal adverse effects. Despite this, TB-500 remains unapproved for therapeutic use in all major markets and is banned by WADA and in horse racing. Evidence is strongest for wound healing and anti-inflammatory effects, with emerging data on cardiac repair in preclinical models.

GHK is a naturally occurring tripeptide first isolated from human plasma, where its levels decline significantly with age. Even without copper complexation, GHK exhibits gene-regulatory activity, affecting over 4,000 genes related to tissue repair, immune function, and anti-inflammatory responses. Research is primarily in cell culture and animal models, with some human studies in wound healing and skin health. Evidence suggests GHK modulates collagen synthesis and antioxidant defenses, but human clinical trials are limited. Its natural presence in plasma supports tolerability, but the evidence base is less robust than TB-500's for specific repair mechanisms.

TB-500 and GHK target distinct research domains despite both being investigated for tissue repair. TB-500 is primarily studied in injury recovery and anti-inflammatory contexts, with a focus on acute wound healing and cardiac repair. GHK is more associated with skin health and anti-aging research, leveraging its gene-regulatory effects on collagen and immune pathways. Overlap occurs in general wound healing studies, but researchers should note that TB-500's mechanism is actin-mediated cell migration, while GHK works through broader transcriptional modulation. This divergence influences experimental design and outcome measures.

TB-500: A safety-focused RCT in 40 healthy adults (2010) found minimal adverse effects with synthetic thymosin beta-4. No significant safety concerns have emerged in published human studies to date; animal and human studies alike report only minor side effects. Common anecdotal effects include injection site pain, lightheadedness, mild headache, nausea, and fatigue. GHK: Well-tolerated in available studies, consistent with its natural presence in human plasma. No serious adverse events have been reported in preclinical or human research. However, the evidence base for GHK safety is smaller, and long-term data are lacking for both peptides.